Top Page
Vertex Pharmaceuticals
(NASDAQ:VRTX)
Vertex Pharmaceuticals (VRTX) vs. SPDR S&P 500 ETF (SPY)
Vertex Pharmaceuticals Business Overview & Revenue Model
Vertex Pharmaceuticals Key Performance Indicators (KPIs)
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Main Street DataVertex Pharmaceuticals Earnings Call Summary
Vertex Pharmaceuticals Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.72B | 11.02B | 9.87B | 8.93B | 7.57B | 6.21B |
| Gross Profit | 10.11B | 9.49B | 8.61B | 7.85B | 6.67B | 5.47B |
| EBITDA | 4.66B | 486.30M | 4.61B | 4.44B | 2.92B | 3.28B |
| Net Income | 3.68B | -535.60M | 3.62B | 3.32B | 2.34B | 2.71B |
Balance Sheet | ||||||
| Total Assets | 24.86B | 22.53B | 22.73B | 18.15B | 13.43B | 11.75B |
| Cash, Cash Equivalents and Short-Term Investments | 6.29B | 6.12B | 11.22B | 10.78B | 7.52B | 6.66B |
| Total Debt | 1.83B | 1.75B | 808.40M | 899.70M | 967.40M | 931.90M |
| Total Liabilities | 7.54B | 6.12B | 5.15B | 4.24B | 3.33B | 3.06B |
| Stockholders Equity | 17.32B | 16.41B | 17.58B | 13.91B | 10.10B | 8.69B |
Cash Flow | ||||||
| Free Cash Flow | 3.34B | -790.30M | 3.28B | 3.93B | 2.41B | 2.99B |
| Operating Cash Flow | 3.72B | -492.60M | 3.54B | 4.13B | 2.64B | 3.25B |
| Investing Cash Flow | -1.48B | -3.77B | -3.14B | -321.10M | -340.90M | 99.39M |
| Financing Cash Flow | -2.58B | -1.49B | -562.20M | -67.70M | -1.48B | -505.28M |
Vertex Pharmaceuticals Technical Analysis
Vertex Pharmaceuticals Risk Analysis
Vertex Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $20.81B | 17.78 | 30.39% | ― | 18.09% | 3563.21% | |
79 Outperform | $69.11B | 15.74 | 15.19% | 0.40% | 2.89% | 0.50% | |
78 Outperform | $103.89B | 28.86 | 22.31% | ― | 10.53% | ― | |
76 Outperform | $51.95B | 40.86 | 24.75% | ― | 89.58% | ― | |
57 Neutral | $58.49B | 1,837.35 | 32.73% | ― | 53.24% | ― | |
53 Neutral | $24.80B | ― | -2.94% | ― | 7.04% | -25.24% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Vertex Pharmaceuticals Corporate Events
Vertex Pharmaceuticals’ earnings call for the third quarter of 2025 painted a picture of optimism and robust growth. The company reported strong financial performance, marked by significant revenue growth across its diverse product portfolio. Notably, advancements in the renal and cystic fibrosis (CF) segments were highlighted as key drivers of this positive sentiment. However, the call also acknowledged certain challenges, including high gross to net impacts and some regulatory and development delays.
Vertex Pharmaceuticals Inc. is a global biotechnology company focused on developing transformative medicines for serious diseases, with a strong presence in the cystic fibrosis market and a robust pipeline in other therapeutic areas.
Vertex Pharmaceuticals Inc. is conducting a Phase 4 clinical study titled ‘A Phase 4, Open-label, Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine As Part of Multimodal Therapy for Acute Pain After Aesthetic or Reconstructive Surgeries.’ The study aims to assess the effectiveness, safety, and tolerability of Suzetrigine (SUZ) in treating acute postoperative pain, highlighting its significance in enhancing postoperative care.
Vertex Pharmaceuticals Inc. is conducting a Phase 2a study titled ‘A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants.’ The study aims to assess the impact of VX-407 on height-adjusted total kidney volume, alongside its safety, tolerability, and pharmacokinetics in patients with ADPKD.
Vertex Pharmaceuticals Inc. is currently conducting a Phase 2 clinical study titled A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy. The study aims to assess the efficacy, safety, and tolerability of VX-993, an oral medication, for treating pain associated with Diabetic Peripheral Neuropathy (DPN).
Vertex Pharmaceuticals Inc. is currently conducting a Phase 2b clinical study titled A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidney Disease. The study aims to assess the efficacy, safety, and tolerability of Inaxaplin in individuals with proteinuric APOL1-mediated kidney disease, a condition that can lead to chronic kidney disease.
Vertex Pharmaceuticals Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy.’ The study aims to assess the long-term safety and effectiveness of Suzetrigine (SUZ) in treating pain associated with Diabetic Peripheral Neuropathy (DPN), a condition that significantly affects quality of life for many patients.
Vertex Pharmaceuticals Inc. is conducting a Phase 1 study titled ‘A Phase 1, Study of VX-828 in Healthy Subjects and in Subjects With Cystic Fibrosis.’ The study aims to evaluate the safety, tolerability, and pharmacokinetics of VX-828, both alone and in combination with other drugs, in healthy participants and those with cystic fibrosis. This study is significant as it explores new treatment avenues for cystic fibrosis, a critical area of need.
Vertex Pharmaceuticals Inc. is currently conducting a clinical study titled ‘A Study to Determine the Prevalence and Clinical Characteristics Associated With PKD1 Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease (ADPKD).’ The study aims to estimate the prevalence and clinical characteristics of PKD1/2 gene variant groups within the ADPKD population, which could provide significant insights into the genetic underpinnings of this condition.
Vertex Pharmaceuticals Inc. is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy.’ The study aims to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) for treating pain associated with diabetic peripheral neuropathy (DPN), a significant concern for diabetic patients.
Vertex Pharmaceuticals Inc. is conducting a Phase 4 clinical study titled ‘A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries.’ The study aims to assess the effectiveness, safety, and tolerability of Suzetrigine as part of multimodal therapy for managing acute pain following laparoscopic or arthroscopic procedures. This research is significant as it could provide a new pain management option for patients undergoing these surgeries.
Vertex Pharmaceuticals Inc., in collaboration with Moderna, is conducting a Phase 1/2 study titled ‘A Phase 1/2 Dose Escalation Study Evaluating the Safety, and Tolerability and Efficacy of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy.’ The study aims to assess the safety, tolerability, and efficacy of VX-522 in adults with cystic fibrosis who do not respond to existing CFTR modulator therapies, marking a significant step in addressing unmet medical needs in this population.
Vertex Pharmaceuticals Inc. is conducting a Phase 2/3 study titled A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease. The study aims to assess the efficacy, safety, tolerability, and pharmacokinetics of VX-147, a drug designed to treat APOL1-mediated proteinuric kidney disease, a condition affecting kidney function.
Vertex Pharmaceuticals Inc. is embarking on a significant clinical study titled ‘A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy.’ The study aims to assess the efficacy, safety, and tolerability of the drug povetacicept in treating primary membranous nephropathy (pMN), a kidney disorder. This research is crucial as it could offer new treatment avenues for pMN, potentially improving patient outcomes.
Vertex Pharmaceuticals Inc. is conducting a study titled ‘An Open-label Extension Study Evaluating the Long-term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type I.’ This study aims to assess the long-term safety and effectiveness of VX-670, a treatment for Myotonic Dystrophy Type I (DM1), highlighting its significance in potentially improving patient outcomes.
Vertex Pharmaceuticals Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of VX-880 in Subjects With Type 1 Diabetes With a Kidney Transplant.’ The study aims to assess the effectiveness, safety, and tolerability of VX-880 in patients who have Type 1 Diabetes and have undergone a kidney transplant, highlighting its potential significance in addressing these complex medical conditions.
Vertex Pharmaceuticals Inc. is conducting a Phase 1 study titled Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants. The study aims to assess how VX-407 affects the pharmacokinetics of various oral contraceptives, including levonorgestrel, norgestimate, norethindrone, and drospirenone, when co-administered. This research is significant as it evaluates both the safety and tolerability of VX-407 in combination with these contraceptives, potentially impacting treatment options for conditions like Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Vertex Pharmaceuticals Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Year of Age and Older.’ The study aims to assess the long-term safety, tolerability, and efficacy of the triple combination therapy VNZ/TEZ/D-IVA in individuals with cystic fibrosis, a genetic disorder affecting the lungs and digestive system.
Vertex Pharmaceuticals Inc. is conducting a study titled ‘A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia.’ The study aims to assess the safety, tolerability, and efficacy of VX-880 in individuals with Type 1 diabetes, particularly those with impaired awareness of hypoglycemia and severe hypoglycemia. This research is significant as it targets a critical need in diabetes management.
Vertex Pharmaceuticals Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX-121/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Through 11 Years of Age.’ The study aims to assess the pharmacokinetics, safety, and tolerability of the VX-121/TEZ/D-IVA combination in young cystic fibrosis patients with at least one triple combination responsive mutation in the CFTR gene, which is crucial for advancing treatment options for this age group.
Vertex Pharmaceuticals Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3 Study to Evaluate Efficacy and Safety of a Single Dose of Exa-cel in Subjects With Severe Sickle Cell Disease, βS/βC Genotype.’ The study aims to assess the efficacy and safety of Exa-cel, a CRISPR-Cas9 modified therapy, in treating severe sickle cell disease (SCD) in adolescents and adults with the βS/βC genotype. This research is significant as it could provide a groundbreaking treatment option for SCD patients.
Vertex Pharmaceuticals Inc. is conducting a Phase 1/2 clinical study titled A Phase 1/2, Randomized, Double-blind, Placebo-controlled Single- and Multiple-dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type 1. The study aims to assess the safety and effectiveness of VX-670 in treating Myotonic Dystrophy Type 1 (DM1), a genetic disorder that affects muscle function.
Vertex Pharmaceuticals Inc. is conducting a Phase 3b study titled ‘A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Transfusion-Dependent β-Thalassemia or Severe Sickle Cell Disease.’ The study aims to assess the safety and efficacy of CTX001, a CRISPR-Cas9 modified stem cell treatment, in patients with transfusion-dependent β-thalassemia (TDT) and severe sickle cell disease (SCD).
Vertex Pharmaceuticals’ latest earnings call painted a picture of robust growth and strategic advancements, with a generally positive sentiment. The company celebrated strong revenue growth and successful product launches, particularly in cystic fibrosis and sickle cell disease, despite facing some challenges in its pain program. Overall, the positive developments in commercial progress and pipeline advancements overshadowed the negatives.
Vertex Pharmaceuticals Inc., a leading biotechnology company, is known for its innovative treatments for serious diseases, particularly in the field of cystic fibrosis and other genetic disorders. The company is headquartered in Boston and has a global presence with research and development sites across various continents.